Age, years |
49 (43-55) |
48 (39-52) |
50 (43-56) |
0.006 |
Male sex, n |
201 (67.0%) |
28 (54.9%) |
173 (69.5%) |
0.044 |
Enrollment site, n
Torino
Spallanzani
Brescia
Milano
Brighton
Sapienza
|
113 (37.7%)
89 (29.6%)
52 (17.3%)
23 (7.7%)
14 (4.7%)
9 (3.0%)
|
20 (39.2%)
23 (45.1%)
5 (9.8%)
3 (5.9%)
0
0
|
93 (37.3%)
66 (26.5%)
47 (18.9%)
20 (8.0%)
14 (5.6%)
9 (3.6%)
|
0.075
|
Calendar year, n
2016-2021
2011-2015
2006-2010
2001-2005
|
116 (38.7%)
144 (48.0%)
30 (10.0%)
10 (3.3%)
|
13 (25.5%)
27 (52.9%)
7 (13.7%)
4 (7.8%)
|
103 (41.4%)
117 (47.0%)
23 (9.2%)
6 (2.4%)
|
0.012
|
LP indication, n
RP
CC without CNS involvement
NCI
|
50 (16.7%)
140 (46.7%)
110 (36.6%)
|
10 (19.6%)
21 (41.2%)
20 (39.2%)
|
40 (16.1%)
119 (47.8%)
90 (36.1%)
|
0.969
|
Plasma HIV-RNA<50 cp/mL, n |
202 (67.3%) |
35 (68.6%) |
167
(67.1%) |
0.829 |
Plasma HIV-RNA, Log10 cp/mL
Overall
When detectable
|
1.69 (1.69-2.15)
2.85 (2.16-4.51)
|
1.69 (1.69-2.16)
2.44 (2.18-3.10)
|
1.69 (1.69-2.14)
3.19 (2.15-5.28)
|
0.958
0.172
|
CSF HIV-RNA<50 cp/mL, n |
195 (65.0%) |
0 |
195 (78.3%) |
- |
CSF HIV-RNA, Log10 cp/mL
Overall
When detectable
|
1.69 (1.69-2.10)
2.54 (2.07-3.49)
|
2.18 (1.97-3.62)
2.18 (1.97-3.62)
|
1.69 (1.69-1.69)
2.63 (2.16-3.45)
|
<0.001
0.201
|
Type of ART regimen, n
PI-2NRTIs
nNRTI-2NRTIs
INSTI-2NRTIs
3 classes-based regimens
≥4 drugs-based regimens
Mono-dual regimens
|
130 (43.3%)
57 (19.0%)
37 (12.3%)
13 (4.3%)
30 (10.0%)
33 (11.0%)
|
27 (52.9%)
10 (19.6%)
3 (5.9%)
3 (5.9%)
3 (5.9%)
5 (9.8%)
|
103 (41.4%)
47 (18.9%)
34 (13.6%)
10 (4.0%)
27 (10.8%)
28 (11.2%)
|
0.123
|
PI-including ART, n
PI-based mono/dual regimens, n
PI-2NRTIs, n
PI-based three-classes regimens, n
PI-based ≥4 drugs-based regimens, n
|
195 (65.0%)
29/33 (87.9%)
130/224 (58.0%)
12/13 (92.3%)
24/30 (80.0%)
|
38 (74.5%)
5/5 (100%)
27/40 (67.5%)
3/3 (100%)
3/3 (100%)
|
157 (63.0%)
24/28 (85.7%)
103/184 (56.0%)
9/10 (90.0%)
21/27 (77.8%)
|
0.119
0.999
0.181
0.999
0.999
|
Number of ARVs
Number of ARVs, n
1-2 drugs
3 drugs
4-5 drugs
|
3 (3-3)
33 (11.0%)
237 (79.0%)
30 (10.0%)
|
3 (3-3)
5 (9.8%)
43 (84.3%)
3 (5.9%)
|
3 (3-3)
28 (11.2%)
194 (77.9%)
27 (10.8%)
|
0.412
0.765
0.307
0.283
|
On first ART regimen, n |
110 (36.7%) |
14 (27.4%) |
96 (38.6%) |
0.135 |
Current CD4+ T-cells count, cells/µL |
310 (139-554) |
310 (215-567) |
310 (122-553) |
0.958 |
Nadir CD4+ T-cells count, cells/µc
Nadir CD4+ T-cells count, n
<100
100-200
201-350
351-500
>500
|
86 (26-199)
159 (53.0%)
68 (22.7%)
43 (14.3%)
20 (6.7%)
10 (3.3%)
|
80 (13-166)
32 (62.7%)
10 (19.6%)
8 (15.7%)
0
1 (2.0%)
|
97 (28-205)
127 (51.0%)
58 (23.3%)
35 (14.1%)
20 (8.0%)
9 (3.6%)
|
0.138
0.084
|
CD4/CD8 ratio |
0.4 (0.2-0.8) |
0.4 (0.3-0.8) |
0.4 (0.2-0.7) |
0.879 |
Duration of ART, years
Duration of ART, n
1-2 years
3-5 years
6-10 years
>10 years
|
5 (2-8)
92 (30.7%)
74 (24.7%)
82 (27.3%)
52 (17.3%)
|
4 (2-6)
18 (35.3%)
17 (33.3%)
14 (27.4%)
2 (3.9%)
|
5 (2-9)
74 (29.7%)
57 (22.9%)
68 (27.3%)
50 (20.1%)
|
0.036
0.030
|
Duration of current ART, months
Duration of current ART, n
<1 year
1-2 years
3-10 years
|
19 (10-43)
144 (48.0%)
82 (27.3%)
74 (24.7%)
|
14 (9-28)
27 (52.9%)
13 (25.5%)
11 (21.6%)
|
19 (10-46)
117 (47.0%)
69 (27.7%)
63 (25.3%)
|
0.219
0.434
|
Plasma HGRT, n
RT RAMs
PI RAMs
|
107 (35.7%)
31 (10.3%)
|
27 (52.9%)
9 (17.6%)
|
80 (32.1%)
22 (8.8%)
|
0.005
0.060
|
Total number of plasma RAMs,
RT
PI
|
0 (0-2)
0 (0-0)
|
1 (0-3)
0 (0-0)
|
0 (0-1)
0 (0-0)
|
0.190
0.156
|
CSF HGRT, n
RT RAMs
PI RAMs
|
24/63 (38.1%)
8/63 (12.7%)
|
12/21 (57.1%)
5/21 (23.8%)
|
12/42 (28.6%)
3/42 (7.1%)
|
0.029
0.063
|
Total number of CSF RAMs,
RT
PI
|
0 (0-1)
0 (0-0)
|
1 (0-3)
0 (0-1)
|
0 (0-1)
0 (0-0)
|
0.177
0.141
|
CPE score |
7 (7-8) |
7 (7-8) |
7 (7-8) |
0.921 |